Payment overview · 2025
General Payments
$4,243.56
99 reported records · 25 companies
Healthcare provider profile · identity verified
Heyer C Devarapalli, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ARLINGTON HEIGHTS, IL · NPI 1588704381
Verified facts
What the public records show
CMS Open Payments records show Heyer C Devarapalli, MD received $4,243.56 in general payments during 2025 across 99 reported records.
Amgen Inc. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $686.47 | 16.2% | 19 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $454.45 | 10.7% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $389.66 | 9.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $333.20 | 7.8% | 8 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $294.15 | 6.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $286.66 | 6.8% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $232.23 | 5.5% | 7 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $208.78 | 4.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $167.18 | 3.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $158.22 | 3.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.00 | 3.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $127.31 | 3.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.90 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $122.57 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.20 | 2.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.48 | 2.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.99 | 2.1% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $68.95 | 1.6% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $33.92 | 0.8% | 2 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $19.29 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.11 | 0.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.04 | 0.5% | 1 | 2025 |
| HARTMANN USA, INC. | Unresolved — no canonical attribution shown | $18.80 | 0.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.51 | 0.4% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $17.49 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,243.56 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $459.67 | 10 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $431.22 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $336.62 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $242.35 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $231.14 | 7 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $188.93 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $188.78 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $167.18 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $158.22 | 4 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $143.55 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $143.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.58 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $127.31 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.90 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $122.57 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $108.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.17 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $90.99 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $82.72 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $80.43 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $75.50 | 8 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $68.95 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.97 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.56 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.57 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $33.92 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| ZETUVIT PLUS 10X10 P10 Normalized: zetuvit plus 10x10 p10 |
Device | HARTMANN USA, INC. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 184 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
184 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 833 | 253 |
| Atorvastatin Calcium | Atorvastatin Calcium | 756 | 224 |
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 449 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 410 | 118 |
| Metformin Hcl | Metformin Hcl | 401 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 333 | 119 |
| Losartan Potassium | Losartan Potassium | 314 | 92 |
| Simvastatin | Simvastatin | 277 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 269 | 77 |
| Montelukast Sodium | Montelukast Sodium | 265 | 94 |
| Gabapentin | Gabapentin | 241 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 217 | 108 |
| Furosemide | Furosemide | 212 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 72 |
| Lisinopril | Lisinopril | 196 | 56 |
| Eliquis | Apixaban | 184 | 45 |
| Glimepiride | Glimepiride | 167 | 51 |
| Omeprazole | Omeprazole | 163 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 51 |
| Jardiance | Empagliflozin | 155 | 47 |
| Carvedilol | Carvedilol | 143 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 29 |
| Alendronate Sodium | Alendronate Sodium | 115 | 31 |
| Famotidine | Famotidine | 109 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 100 | 24 |
| Allopurinol | Allopurinol | 98 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 26 |
| Tramadol Hcl | Tramadol Hcl | 84 | 15 |
| Sertraline Hcl | Sertraline Hcl | 80 | 28 |
| Donepezil Hcl | Donepezil Hcl | 78 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 36 |
| Benazepril Hcl | Benazepril Hcl | 72 | 24 |
| Finasteride | Finasteride | 71 | 22 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 70 | 18 |
| Trazodone Hcl | Trazodone Hcl | 69 | 22 |
| Alprazolam | Alprazolam | 68 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 40 |
| Ozempic | Semaglutide | 63 | 16 |
| Buspirone Hcl | Buspirone Hcl | 61 | 26 |
| Nifedipine Er | Nifedipine | 61 | 19 |
| Metformin Hcl Er | Metformin Hcl | 59 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 15 |
| Enalapril Maleate | Enalapril Maleate | 57 | 12 |
| Mirtazapine | Mirtazapine | 57 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 22 |
| Spironolactone | Spironolactone | 56 | 18 |
| Irbesartan | Irbesartan | 55 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 19 |
| Potassium Chloride | Potassium Chloride | 53 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 16 |
| Atenolol | Atenolol | 51 | 13 |
| Clonidine Hcl | Clonidine Hcl | 51 | 17 |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 21 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 49 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | 11 |
| Meclizine Hcl | Meclizine Hcl | 48 | 26 |
| Telmisartan | Telmisartan | 46 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Prednisone | Prednisone | 38 | 25 |
| Methylprednisolone | Methylprednisolone | 37 | 36 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 14 |
| Azithromycin | Azithromycin | 35 | 31 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 25 |
| Jantoven | Warfarin Sodium | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Naproxen | Naproxen | 28 | 12 |
| Nystatin | Nystatin | 27 | 18 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 11 |
| Meloxicam | Meloxicam | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Colchicine | Colchicine | 20 | 11 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | 12 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,243.56 · 99 records | Amgen Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, COLLAGENASE SANTYL, COMIRNATY, CREON, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GRAFIX PL, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Kimyrsa, Korlym, LINZESS, MOUNJARO, NUZYRA, OASIS, OTEZLA, Orbactiv, Ozempic, PREVNAR 20, PROLIA, REPATHA, REXULTI, Rezzayo, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, STRAVIX PL, Symbravo, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XIFAXAN, YUPELRI, ZETUVIT PLUS 10X10 P10, ZORYVE, Zubsolv | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error